Zylö Receives $294,000 NIH Phase I Grant to Advance its Cutaneous Lupus Program
GREENVILLE, SC, May 31, 2023 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod® topical delivery platform, has been awarded a two-year $294,000 Small Business Technology Transfer Research (STTR) grant to: (i) demonstrate that a formulation of N-acylethanolamine (AEA or anandamide) loaded into Zylö’s novel Z-pod delivery system is efficacious (and well tolerated) in a new mouse model of cutaneous lupus developed at Yale University, and (ii) conduct preliminary stability studies to prepare for an eventual investigational new drug (IND) application to the FDA. The grant is sponsored by the NIH’s National Institute of Arthritis and Musculoskeletal/Skin Disease under Award 1R41AR082749.
- The grant is sponsored by the NIH’s National Institute of Arthritis and Musculoskeletal/Skin Disease under Award 1R41AR082749.
- The principal investigator of the project is Andrew Draganski, Ph.D., Zylö’s head of product development.
- Dr. Werth is one of the world’s foremost authorities on cutaneous lupus.
- Approximately 500,000 people in the U.S. suffer from cutaneous lupus erythematosus (CLE), with a significant impact on quality of life.